annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
982030887 | rs3761555 | rs3761555 | GRIA3 | CT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030887 |
982030887 | rs3761555 | rs3761555 | GRIA3 | TT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030887 |
982030900 | rs3761554 | rs3761554 | GRIA3 | CC | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030900 |
982030900 | rs3761554 | rs3761554 | GRIA3 | CT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030900 |
982030900 | rs3761554 | rs3761554 | GRIA3 | TT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030900 |
982030907 | rs502434 | rs502434 | GRIA3 | CC | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CC genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030907 |
982030907 | rs502434 | rs502434 | GRIA3 | CT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030907 |
982030907 | rs502434 | rs502434 | GRIA3 | TT | 3 | Efficacy | antidepressants;Selective serotonin reuptake inhibitors;venlafaxine | Major Depressive Disorder | Patients with the TT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.clinpgx.org/clinicalAnnotation/982030907 |
982030916 | rs948854 | rs948854 | GAL | CC | 3 | Efficacy | antidepressants;benzodiazepine derivatives;mirtazapine;Selective serotonin reuptake inhibitors | Major Depressive Disorder | Female patients with the CC genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also... | https://www.clinpgx.org/clinicalAnnotation/982030916 |
982030916 | rs948854 | rs948854 | GAL | CT | 3 | Efficacy | antidepressants;benzodiazepine derivatives;mirtazapine;Selective serotonin reuptake inhibitors | Major Depressive Disorder | Female patients with the CT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also... | https://www.clinpgx.org/clinicalAnnotation/982030916 |
982030916 | rs948854 | rs948854 | GAL | TT | 3 | Efficacy | antidepressants;benzodiazepine derivatives;mirtazapine;Selective serotonin reuptake inhibitors | Major Depressive Disorder | Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also... | https://www.clinpgx.org/clinicalAnnotation/982030916 |
982030948 | rs962369 | rs962369 | BDNF | CC | 3 | Toxicity | escitalopram;nortriptyline | Major Depressive Disorder | Patients with the CC genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. | https://www.clinpgx.org/clinicalAnnotation/982030948 |
982030948 | rs962369 | rs962369 | BDNF | CT | 3 | Toxicity | escitalopram;nortriptyline | Major Depressive Disorder | Patients with the CT genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. | https://www.clinpgx.org/clinicalAnnotation/982030948 |
982030948 | rs962369 | rs962369 | BDNF | TT | 3 | Toxicity | escitalopram;nortriptyline | Major Depressive Disorder | Patients with the TT genotype and depression may have decreased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. | https://www.clinpgx.org/clinicalAnnotation/982030948 |
982030971 | rs9859552 | rs9859552 | P2RY12 | GG | 3 | Efficacy | cangrelor | null | Patients with the GG genotype may have more inhibition of platelet aggregation with crangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor. | https://www.clinpgx.org/clinicalAnnotation/982030971 |
982030971 | rs9859552 | rs9859552 | P2RY12 | GT | 3 | Efficacy | cangrelor | null | No information is reported for the GT genotype. However, patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor. | https://www.clinpgx.org/clinicalAnnotation/982030971 |
982030971 | rs9859552 | rs9859552 | P2RY12 | TT | 3 | Efficacy | cangrelor | null | Patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor. | https://www.clinpgx.org/clinicalAnnotation/982030971 |
982030990 | rs9483947 | rs9483947 | MAP3K5 | CC | 3 | Efficacy | hydroxyurea | Beta-thalassemia and related diseases | Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982030990 |
982030990 | rs9483947 | rs9483947 | MAP3K5 | CT | 3 | Efficacy | hydroxyurea | Beta-thalassemia and related diseases | Patients with the CT genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or TT. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982030990 |
982030990 | rs9483947 | rs9483947 | MAP3K5 | TT | 3 | Efficacy | hydroxyurea | Beta-thalassemia and related diseases | Patients with the TT genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982030990 |
982030998 | rs9376230 | rs9376230 | MAP3K5 | AA | 3 | Efficacy | hydroxyurea | Beta-thalassemia and related diseases | Patients with the AA genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype AC. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982030998 |
982030998 | rs9376230 | rs9376230 | MAP3K5 | AC | 3 | Efficacy | hydroxyurea | Beta-thalassemia and related diseases | Patients with the AC genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or AA. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982030998 |
982030998 | rs9376230 | rs9376230 | MAP3K5 | CC | 3 | Efficacy | hydroxyurea | Beta-thalassemia and related diseases | Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982030998 |
982031013 | rs8192440 | rs8192440 | CRY1 | AA | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031013 |
982031013 | rs8192440 | rs8192440 | CRY1 | GA | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GA genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031013 |
982031013 | rs8192440 | rs8192440 | CRY1 | GG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031013 |
982031026 | rs7787082 | rs7787082 | ABCB1 | AA | 3 | Efficacy | amitriptyline;citalopram;paroxetine;venlafaxine | Depressive Disorder | Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission. | https://www.clinpgx.org/clinicalAnnotation/982031026 |
982031026 | rs7787082 | rs7787082 | ABCB1 | AG | 3 | Efficacy | amitriptyline;citalopram;paroxetine;venlafaxine | Depressive Disorder | Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission. | https://www.clinpgx.org/clinicalAnnotation/982031026 |
982031026 | rs7787082 | rs7787082 | ABCB1 | GG | 3 | Efficacy | amitriptyline;citalopram;paroxetine;venlafaxine | Depressive Disorder | Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission. | https://www.clinpgx.org/clinicalAnnotation/982031026 |
982031034 | rs6809699 | rs6809699 | P2RY12 | AA | 3 | Efficacy | clopidogrel | Coronary Artery Disease | Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982031034 |
982031034 | rs6809699 | rs6809699 | P2RY12 | AC | 3 | Efficacy | clopidogrel | Coronary Artery Disease | Patients with the AC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982031034 |
982031034 | rs6809699 | rs6809699 | P2RY12 | CC | 3 | Efficacy | clopidogrel | Coronary Artery Disease | Patients with the CC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982031034 |
982031045 | rs1799983 | rs1799983 | NOS3 | GG | 3 | Toxicity | aspirin;Beta Blocking Agents;clopidogrel;HMG-CoA reductase inhibitors | Coronary Artery Disease | Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also in... | https://www.clinpgx.org/clinicalAnnotation/982031045 |
982031045 | rs1799983 | rs1799983 | NOS3 | TG | 3 | Toxicity | aspirin;Beta Blocking Agents;clopidogrel;HMG-CoA reductase inhibitors | Coronary Artery Disease | Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patien... | https://www.clinpgx.org/clinicalAnnotation/982031045 |
982031045 | rs1799983 | rs1799983 | NOS3 | TT | 3 | Toxicity | aspirin;Beta Blocking Agents;clopidogrel;HMG-CoA reductase inhibitors | Coronary Artery Disease | Male patients with the TT genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patien... | https://www.clinpgx.org/clinicalAnnotation/982031045 |
982031106 | rs35599367 | rs35599367 | CYP3A4 | AA | 3 | Other | midazolam | Neoplasms | Patients with the AA genotype were not studied, however they may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam. | https://www.clinpgx.org/clinicalAnnotation/982031106 |
982031106 | rs35599367 | rs35599367 | CYP3A4 | AG | 3 | Other | midazolam | Neoplasms | Patients with the AG genotype and tumors may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam. | https://www.clinpgx.org/clinicalAnnotation/982031106 |
982031106 | rs35599367 | rs35599367 | CYP3A4 | GG | 3 | Other | midazolam | Neoplasms | Patients with the GG genotype and tumors may have increased metabolism of midazolam as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of midazolam. | https://www.clinpgx.org/clinicalAnnotation/982031106 |
982031125 | rs35599367 | rs35599367 | CYP3A4 | AA | 3 | Other | erythromycin | Neoplasms | Patients with the AA genotype were not studied, however they may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. | https://www.clinpgx.org/clinicalAnnotation/982031125 |
982031125 | rs35599367 | rs35599367 | CYP3A4 | AG | 3 | Other | erythromycin | Neoplasms | Patients with the AG genotype and tumors may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. | https://www.clinpgx.org/clinicalAnnotation/982031125 |
982031125 | rs35599367 | rs35599367 | CYP3A4 | GG | 3 | Other | erythromycin | Neoplasms | Patients with the GG genotype and tumors may have increased metabolism of erythromycin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. | https://www.clinpgx.org/clinicalAnnotation/982031125 |
982031241 | rs3794271 | rs3794271 | SLCO1C1 | AA | 3 | Efficacy | Tumor necrosis factor alpha (TNF-alpha) inhibitors | Arthritis, Psoriatic;Rheumatoid arthritis | Patients with the AA genotype and arthritis may have increased response to TNF inhibitors as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | https://www.clinpgx.org/clinicalAnnotation/982031241 |
982031241 | rs3794271 | rs3794271 | SLCO1C1 | AG | 3 | Efficacy | Tumor necrosis factor alpha (TNF-alpha) inhibitors | Arthritis, Psoriatic;Rheumatoid arthritis | Patients with the AG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | https://www.clinpgx.org/clinicalAnnotation/982031241 |
982031241 | rs3794271 | rs3794271 | SLCO1C1 | GG | 3 | Efficacy | Tumor necrosis factor alpha (TNF-alpha) inhibitors | Arthritis, Psoriatic;Rheumatoid arthritis | Patients with the GG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | https://www.clinpgx.org/clinicalAnnotation/982031241 |
982031308 | rs4532 | rs4532 | DRD1 | CC | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CC genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982031308 |
982031308 | rs4532 | rs4532 | DRD1 | CT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982031308 |
982031308 | rs4532 | rs4532 | DRD1 | TT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the TT genotype and Bipolar Disorder may have an increased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982031308 |
982031323 | rs334558 | rs334558 | GSK3B | AA | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031323 |
982031323 | rs334558 | rs334558 | GSK3B | AG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031323 |
982031323 | rs334558 | rs334558 | GSK3B | GG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031323 |
982031330 | rs2826494 | rs2826494 | null | CC | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031330 |
982031330 | rs2826494 | rs2826494 | null | GC | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031330 |
982031330 | rs2826494 | rs2826494 | null | GG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031330 |
982031346 | rs2499984 | rs2499984 | OR52J2P;OR52J3 | AA | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031346 |
982031346 | rs2499984 | rs2499984 | OR52J2P;OR52J3 | AG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031346 |
982031346 | rs2499984 | rs2499984 | OR52J2P;OR52J3 | GG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031346 |
982031374 | rs2314339 | rs2314339 | NR1D1;THRA | CC | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031374 |
982031374 | rs2314339 | rs2314339 | NR1D1;THRA | TC | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the TC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031374 |
982031374 | rs2314339 | rs2314339 | NR1D1;THRA | TT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031374 |
982031407 | rs2284018 | rs2284018 | CACNG2 | CC | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031407 |
982031407 | rs2284018 | rs2284018 | CACNG2 | CT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031407 |
982031407 | rs2284018 | rs2284018 | CACNG2 | TT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982031407 |
982031517 | rs352428 | rs352428 | null | AA | 3 | Efficacy | citalopram;escitalopram | Major Depressive Disorder | Patients with the AA genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram. | https://www.clinpgx.org/clinicalAnnotation/982031517 |
982031517 | rs352428 | rs352428 | null | AG | 3 | Efficacy | citalopram;escitalopram | Major Depressive Disorder | Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram. | https://www.clinpgx.org/clinicalAnnotation/982031517 |
982031517 | rs352428 | rs352428 | null | GG | 3 | Efficacy | citalopram;escitalopram | Major Depressive Disorder | Patients with the GG genotype and depression may be more likely to respond to citalopram or escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram. | https://www.clinpgx.org/clinicalAnnotation/982031517 |
982031723 | rs6431558 | rs6431558 | UGT1A8 | CC | 3 | Other | ABT-751 | Neoplasms | Patients with the CC genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751. | https://www.clinpgx.org/clinicalAnnotation/982031723 |
982031723 | rs6431558 | rs6431558 | UGT1A8 | CT | 3 | Other | ABT-751 | Neoplasms | Patients with the CT genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751. | https://www.clinpgx.org/clinicalAnnotation/982031723 |
982031723 | rs6431558 | rs6431558 | UGT1A8 | TT | 3 | Other | ABT-751 | Neoplasms | Patients with the TT genotype may have decreased glucuronidation metabolic ratios of ABT-751 as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence clearance of ABT-751. | https://www.clinpgx.org/clinicalAnnotation/982031723 |
982031741 | rs7439366 | rs7439366 | UGT2B7 | CC | 4 | Metabolism/PK | valproic acid | Epilepsy | The current evidence base suggests that there is no significant association between the rs7439366 CC genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include eviden... | https://www.clinpgx.org/clinicalAnnotation/982031741 |
982031741 | rs7439366 | rs7439366 | UGT2B7 | CT | 4 | Metabolism/PK | valproic acid | Epilepsy | The current evidence base suggests that there is no significant association between the rs7439366 CT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include eviden... | https://www.clinpgx.org/clinicalAnnotation/982031741 |
982031741 | rs7439366 | rs7439366 | UGT2B7 | TT | 4 | Metabolism/PK | valproic acid | Epilepsy | The current evidence base suggests that there is no significant association between the rs7439366 TT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include eviden... | https://www.clinpgx.org/clinicalAnnotation/982031741 |
982031767 | rs762551 | rs762551 | CYP1A2 | AA | 3 | Dosage;Toxicity | paroxetine | Major Depressive Disorder | Patients with AA genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982031767 |
982031767 | rs762551 | rs762551 | CYP1A2 | AC | 3 | Dosage;Toxicity | paroxetine | Major Depressive Disorder | Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982031767 |
982031767 | rs762551 | rs762551 | CYP1A2 | CC | 3 | Dosage;Toxicity | paroxetine | Major Depressive Disorder | Patients with CC genotype may require a decreased dose of paroxetine and may have an decreased risk of fatigue when treated with paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982031767 |
982031795 | rs568408 | rs568408 | IL12A | AA | 3 | Toxicity | mycophenolate mofetil | Kidney Transplantation | Patients with the AA genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil. | https://www.clinpgx.org/clinicalAnnotation/982031795 |
982031795 | rs568408 | rs568408 | IL12A | AG | 3 | Toxicity | mycophenolate mofetil | Kidney Transplantation | Patients with the AG genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil. | https://www.clinpgx.org/clinicalAnnotation/982031795 |
982031795 | rs568408 | rs568408 | IL12A | GG | 3 | Toxicity | mycophenolate mofetil | Kidney Transplantation | Patients with the GG genotype may have a decreased, but not absent, risk of anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil. | https://www.clinpgx.org/clinicalAnnotation/982031795 |
982031855 | rs588765 | rs588765 | CHRNA5 | CC | 3 | Efficacy | Drugs used in nicotine dependence;nicotine;varenicline | Tobacco Use Disorder | Patients with the CC genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the TT genotype. However this has been contradicted in some studies. Other clinical and genetic factor... | https://www.clinpgx.org/clinicalAnnotation/982031855 |
982031855 | rs588765 | rs588765 | CHRNA5 | CT | 3 | Efficacy | Drugs used in nicotine dependence;nicotine;varenicline | Tobacco Use Disorder | Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors... | https://www.clinpgx.org/clinicalAnnotation/982031855 |
982031855 | rs588765 | rs588765 | CHRNA5 | TT | 3 | Efficacy | Drugs used in nicotine dependence;nicotine;varenicline | Tobacco Use Disorder | Patients with the TT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies. Other clinical and genetic factor... | https://www.clinpgx.org/clinicalAnnotation/982031855 |
982031864 | rs1051730 | rs1051730 | CHRNA3 | AA | 3 | Efficacy | Drugs used in nicotine dependence;nicotine | Tobacco Use Disorder | Patients with the AA genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and geneti... | https://www.clinpgx.org/clinicalAnnotation/982031864 |
982031864 | rs1051730 | rs1051730 | CHRNA3 | AG | 3 | Efficacy | Drugs used in nicotine dependence;nicotine | Tobacco Use Disorder | Patients with the AG genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and geneti... | https://www.clinpgx.org/clinicalAnnotation/982031864 |
982031864 | rs1051730 | rs1051730 | CHRNA3 | GG | 3 | Efficacy | Drugs used in nicotine dependence;nicotine | Tobacco Use Disorder | Patients with the GG genotype may have decreased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the AA or AG genotypes. However, another study failed to find an association between this variant and response to NRT. Other clinical and... | https://www.clinpgx.org/clinicalAnnotation/982031864 |
982031956 | rs8832 | rs8832 | IL4R | AA | 3 | Efficacy | pitrakinra | Asthma | Patients with the AA genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/982031956 |
982031956 | rs8832 | rs8832 | IL4R | AG | 3 | Efficacy | pitrakinra | Asthma | Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/982031956 |
982031956 | rs8832 | rs8832 | IL4R | GG | 3 | Efficacy | pitrakinra | Asthma | Patients with the GG genotype and Asthma may be more likely to respond when treated with pitrakinra as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/982031956 |
982032228 | rs10835210 | rs10835210 | BDNF | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032228 |
982032228 | rs10835210 | rs10835210 | BDNF | AC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032228 |
982032228 | rs10835210 | rs10835210 | BDNF | CC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032228 |
982032257 | rs7934165 | rs7934165 | BDNF | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032257 |
982032257 | rs7934165 | rs7934165 | BDNF | AG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032257 |
982032257 | rs7934165 | rs7934165 | BDNF | GG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032257 |
982032306 | rs1491850 | rs1491850 | BDNF | CC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032306 |
982032306 | rs1491850 | rs1491850 | BDNF | CT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032306 |
982032306 | rs1491850 | rs1491850 | BDNF | TT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032306 |
982032329 | rs2120266 | rs2120266 | NTRK2 | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032329 |
982032329 | rs2120266 | rs2120266 | NTRK2 | AG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032329 |
982032329 | rs2120266 | rs2120266 | NTRK2 | GG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032329 |
982032396 | rs2289658 | rs2289658 | NTRK2 | CC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032396 |
982032396 | rs2289658 | rs2289658 | NTRK2 | CT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032396 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.